Bowcock A.M. Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology. <...> Wagner E.F., Schonthaler H.B., Guinea-Viniegra J., Tschachler E. Psoriasis: what we have learned from mouse models. <...> Ghoreschi K., Weigert C., Rцcken M. mmunopathogenesis and role of T cells in psoriasis. <...> Menter A., Gottlieb A., Feldman S.R., Van Voorhees A. S., Leonardi C.L., Gordon K.B., et al. <...> Guidelines of care for the management of psoriasis and psoriatic arthritis: Section I. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <...> The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. <...> Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <...> Papp K., Langley R., Lebwohl M., Krueger G.G., Szapary P., Yeilding N.; PHOENIX 2 study investigators. <...> Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). <...> Reich K., Burden A.D., Eaton J.N., Hawkins N.S. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. <...> Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al.; EXPRESS study investigators. <...> Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <...> Hsu L., Snodgrass B.T., Armstrong A.W. Antidrag antibodies in psoriasis: a systematic review. <...> Menter A., Tyring S., Gordon K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <...> Papp K.A., Tyring S., Lahfa M. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. <...> Signorovitch J.E., Betts K.A., Yan Y.S., LeReun C., Sundaram M., Wu E.Q., Mulani P. Comparative efficacy of biologic treatments for moderate to severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response <...>